Michael Härter, Michael Koch, Jan Dreher, Anja Giese, Fabian Göricke, Klemens Lustig, Jürgen Klar, Ambra Pozzi, Corina M. Borza
{"title":"Discovery of a highly potent DDR1/2 inhibitor with good kinase selectivity and strong anti-inflammatory efficacy in a mouse model of acute kidney injury","authors":"Michael Härter, Michael Koch, Jan Dreher, Anja Giese, Fabian Göricke, Klemens Lustig, Jürgen Klar, Ambra Pozzi, Corina M. Borza","doi":"10.1016/j.ejmech.2026.119470","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119470","url":null,"abstract":"Discoidin Domain Receptors 1 and 2 (DDR1/2) are receptor tyrosine kinases activated by collagen. Their upregulation and activation are observed in various human diseases, including kidney disease, with most evidence existing for DDR1. Several small-molecule DDR1 inhibitors have shown efficacy in diverse animal models of kidney injury and disease; yet none of them have entered clinical trials. Here, we report on the discovery of a new chemical series of small-molecule DDR inhibitors, based on a dihydropyridopyrimidinyl-benzamide scaffold, and its subsequent hit-to-lead optimization. The chemical series was identified from an in-house screening library by independent virtual and ultra-high throughput screening. The initial screening hit was optimized for potency, kinase selectivity and pharmacokinetic properties, and gave rise to a lead compound suitable for pharmacological <ce:italic>in vivo</ce:italic> studies. The lead compound BAY-852 inhibited collagen-induced receptor activation in kidney cells with IC<ce:inf loc=\"post\">50</ce:inf> values below 1 nM, consistent with the potencies in biochemical assays. In a model of ischemia reperfusion-induced acute kidney injury (AKI), BAY-852 – when administered <ce:italic>via</ce:italic> oral gavage at 2 mg/kg – blocked injury-induced DDR1 phosphorylation, reduced the levels of KIM-1, a marker of tubular injury, and reduced inflammatory cell infiltration. The low effective <ce:italic>in vivo</ce:italic> dose confirms the high potency and the excellent pharmacokinetic properties of BAY-852. Based on these results, the lead compound shows promise and warrants further exploration in animal models of human diseases where DDR1 is upregulated and activated.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"22 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149292304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashna Garg, Nathalia Fidelis Vieira de Sa, Ananya Shibana Thennarasu, Kathryn Takemura, Gabriel S. Matos, Jacob Acosta, Neelu Singh, Caroline Correa De Almeida, Nivea Pereira De Sa, Maurizio Del Poeta, Iwao Ojima
{"title":"Design, Synthesis and SAR Studies of N’-(Heteroarylsalicylidene)- and N’-(Fused-heterobicyclosalicylidene)-N-arenecarbohydrazides as Next-Generation Broad-Spectrum Antifungal Agents","authors":"Ashna Garg, Nathalia Fidelis Vieira de Sa, Ananya Shibana Thennarasu, Kathryn Takemura, Gabriel S. Matos, Jacob Acosta, Neelu Singh, Caroline Correa De Almeida, Nivea Pereira De Sa, Maurizio Del Poeta, Iwao Ojima","doi":"10.1016/j.ejmech.2026.119426","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119426","url":null,"abstract":"The design, synthesis, biological evaluations and SAR study of <ce:italic>N’</ce:italic>-heteroarylsalicylidene- and <ce:italic>N′</ce:italic>-(fused-heterobicyclosalicylidene)-<ce:italic>N</ce:italic>-arenecarbohydrazides, as the next-generation broad-spectrum antifungal agents effective against fungal pathogens in WHO’s Fungal Priority Pathogen List (FPPL), are reported. A library of 58 compounds thus synthesized were examined for their potency against <ce:italic>C. neoformans, C. albicans</ce:italic> and <ce:italic>A. fumigatus</ce:italic> to select highly potent broad-spectrum lead compounds. Against <ce:italic>C. neoformans</ce:italic>, 52 out of 58 compounds show high potency and 7 compounds, bearing furan and thiazole on the ring B, exhibited extremely high potency (MIC<ce:inf loc=\"post\">80</ce:inf> 0.001∼0.007 μg/mL). A good number of compounds showed high potency against <ce:italic>C. albicans</ce:italic> (MIC<ce:inf loc=\"post\">80</ce:inf><ce:italic>≤</ce:italic> 0.5 μg/mL). In contrast, only 10 out of 58 compounds showed good activity against <ce:italic>A. fumigatus</ce:italic> (MIC<ce:inf loc=\"post\">80</ce:inf> <1 μg/mL).","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"85 1 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149292310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to \"AVP-GPT2: Prompt-conditioned fine-tuning of a GPT-2 protein language model for antiviral peptide identification\" [Eur. J. Med. Chem. 320 (2026) 119352].","authors":"Maryam, Hamza Zahid, Kil To Chong, Hilal Tayara","doi":"10.1016/j.ejmech.2026.119409","DOIUrl":"10.1016/j.ejmech.2026.119409","url":null,"abstract":"","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":" ","pages":"119409"},"PeriodicalIF":6.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CADD-Based Discovery of Novel Heterocyclic Pyrimidine-Based CDK4/6 Inhibitors: Design, Synthesis, and Anti-Breast Cancer Activity Studies","authors":"Xinya Lv , Xiaoling Huang , Lulu Tian , Shidi Xu , Yujie Zhan , Hanrui Hou , Dajun Zhang , Linxiao Wang , Shan Xu","doi":"10.1016/j.ejmech.2026.118932","DOIUrl":"10.1016/j.ejmech.2026.118932","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Forty novel heterocyclic pyrimidine compounds were designed, screened, and synthesized using a CADD strategy as highly potent CDK4/6 inhibitors.</div></span></li><li><span>•</span><span><div>The lead compound 3c exhibits potent CDK4/6 kinase inhibitory activity, with an IC50 in the nM range.</div></span></li><li><span>•</span><span><div>Compound 3c induces G1 phase arrest and apoptosis in MCF-7 cancer cells by inhibiting the phosphorylation of the Rb protein.</div></span></li><li><span>•</span><span><div>The lead compound demonstrates good in vivo tumor-suppressing activity and acceptable biosafety, making it worthy of further development.</div></span></li></ul></div><div><div>Cyclin-dependent kinase 4/6 (CDK4/6) plays a pivotal role in cell cycle regulation, and its abnormal activation is closely associated with the initiation and progression of breast cancer.1 However, the limited number of clinically available CDK4/6 inhibitors restricts treatment options. This study focuses on the design, synthesis, and antitumor activity investigation of novel CDK4/6 inhibitors.Employing computer-aided drug design (CADD) strategies and utilizing drug-like and bioisostere principles, we innovatively introduced pyridine-2-aminopyrimidine, thieno[3,2-d]pyrimidine, and pyrazolo[1,5-a]pyrimidine as core skeletal structures to design and screen 250 compound molecules. Based on computational results, including molecular docking and MM/GBSA binding free energy, 40 potential novel CDK4/6 inhibitors were selected for synthesis.Cellular assays validated that compound 3c exhibited the strongest inhibitory activity against CDK4/6 in breast cancer cell lines, with IC<sub>50</sub> values of 0.11 ± 0.01 μM (MCF-7), 0.21 ± 0.01 μM (4T1), and 0.12 ± 0.01 μM (MDA-MB-231). And compound <strong>3c</strong> demonstrated favorable CDK4/6 inhibition rates and showed a certain degree of selectivity among 23 kinases. In vitro mechanistic studies revealed that <strong>3c</strong> consistently inhibited cell colony formation and migration. Furthermore, <strong>3c</strong> effectively arrested the MCF-7 cell cycle at the G1 phase and induced apoptosis. In the MCF-7 xenograft model, compound <strong>3c</strong> achieved a tumor inhibition rate of 45.20%, highlighting its significant potential as a therapeutic CDK4/6 inhibitor.</div></div><div>Cyclin-dependent kinase 4/6 (CDK4/6) plays a pivotal role in cell cycle regulation, and its abnormal activation is closely associated with the initiation and progression of breast cancer.1 However, the limited number of clinically available CDK4/6 inhibitors restricts treatment options. This study focuses on the design, synthesis, and antitumor activity investigation of novel CDK4/6 inhibitors.Employing computer-aided drug design (CADD) strategies and utilizing drug-like and bioisostere principles, we innovatively introduced pyridine-2-aminopyrimidine, thieno[3,2-d]pyrimidine, and pyrazolo[1,5-a]pyrimidine as co","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"315 ","pages":"Article 118932"},"PeriodicalIF":5.9,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147999287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junghwan Choi , Sunwoo Lee , Yong-Yea Park , Jihun Kim , Haein Kim , Kyeongwon Moon , Sunyoung Park , Eun Kyung Yoo , Chang Won Min , Hyouk Woo Lee , Hyun-Ju Park , Pargat Singh , Sungjoon Kim , Chan Sun Park , In Su Kim
{"title":"Discovery of novel ENPP1 inhibitors with benzotriazole core for cancer immunotherapy","authors":"Junghwan Choi , Sunwoo Lee , Yong-Yea Park , Jihun Kim , Haein Kim , Kyeongwon Moon , Sunyoung Park , Eun Kyung Yoo , Chang Won Min , Hyouk Woo Lee , Hyun-Ju Park , Pargat Singh , Sungjoon Kim , Chan Sun Park , In Su Kim","doi":"10.1016/j.ejmech.2026.118666","DOIUrl":"10.1016/j.ejmech.2026.118666","url":null,"abstract":"<div><div>The cGAS-STING signaling pathway is an essential mechanism in the recruitment and activation of innate and adaptive immune cells to exert an antitumor response in cancer immunotherapy. cGAMP is a crucial immunotransmitter, which is potentially degraded by ENPP1, resulting in the deactivation of STING-mediated antitumor immune responses. We herein describe the design, synthesis, and biological evaluation of novel ENPP1 inhibitors containing a benzotriazole core and a sulfonimidamide Zn binder. Notably, compound <strong>44a</strong> demonstrated potent and selective ENPP1 inhibition with an IC<sub>50</sub> value of 13.1 nM and effectively activated the STING pathway in HCT116-Dual™ cells. Additionally, compound <strong>44a</strong> exhibited a notable release of cytokines in THP-1 cell lines, thereby enhancing the innate immune response. The oral administration of compound <strong>44a</strong> displayed remarkable antitumor efficacy in the MC38 syngeneic mouse model without notable toxicity. Therefore, compound <strong>44a</strong> can be considered a promising candidate as a selective and orally bioavailable ENPP1 inhibitor.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118666"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146153257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weiping Lyu , Haoming Qin , Xiaonan Zhou , Yihan Zhang , Dehua Lu , Yongxiang Shao , Yanming Chen , Mingxiu Liang , Qi Li , Xiaowei Chi , Liangren Zhang , Cheng Shi , Zhenming Liu
{"title":"Xanthine oxidase inhibitors for gout: Applications and novel drug development","authors":"Weiping Lyu , Haoming Qin , Xiaonan Zhou , Yihan Zhang , Dehua Lu , Yongxiang Shao , Yanming Chen , Mingxiu Liang , Qi Li , Xiaowei Chi , Liangren Zhang , Cheng Shi , Zhenming Liu","doi":"10.1016/j.ejmech.2026.118619","DOIUrl":"10.1016/j.ejmech.2026.118619","url":null,"abstract":"<div><div>Hyperuricemia is a well-established direct trigger of gouty arthritis. Xanthine oxidase (XO), the rate-limiting enzyme in uric acid production, represents a core therapeutic target for gout. Although XO inhibitors like allopurinol and febuxostat are widely-used clinically, their limitations, including severe hypersensitivity and cardiovascular risks, necessitate the continuous pursuit of safer and more efficient agents. This review provides a systematic and critical assessment of recent advances in XO inhibitor research, proposing for the first time a unified classification framework based on the evolution of drug design strategies. We comprehensively cover diverse chemical entities, from structure-based, rationally designed compounds to natural products and their corresponding analogs, with a particular emphasis on cutting-edge strategies designed to overcome existing drawbacks. These include dual-target inhibitors (e.g., targeting XO/URAT1 or XO/NLRP3) and drug repurposing. By delving into the structure-activity relationships within each inhibitor class, we identify crucial pharmacophores and optimization principles. Finally, the review offers a forward-looking perspective, critically discussing current research challenges and outlining future directions, such as leveraging artificial intelligence and advanced computational simulations for lead optimization. This work is intended to serve as a clear theoretical blueprint and a practical source of inspiration for medicinal chemists designing the next generation of highly effective and low-toxicity anti-gout therapeutics.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118619"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lei Xu , Mengmeng Wang , Yanshuo Cheng , Hanhan Kuang , Yijing Zhu , Ning Liu , Qianqian Wang , Shicong Li , Jiefu Wang , Junfeng Wang , Ziqi Huang , Ranlu Liu , Shuangwei Liu , Kun Zhang , Guang Yang
{"title":"Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer","authors":"Lei Xu , Mengmeng Wang , Yanshuo Cheng , Hanhan Kuang , Yijing Zhu , Ning Liu , Qianqian Wang , Shicong Li , Jiefu Wang , Junfeng Wang , Ziqi Huang , Ranlu Liu , Shuangwei Liu , Kun Zhang , Guang Yang","doi":"10.1016/j.ejmech.2026.118617","DOIUrl":"10.1016/j.ejmech.2026.118617","url":null,"abstract":"<div><div>Androgen receptor splice variant 7 (AR-V7) plays a crucial role in the malignant progression of castration-resistant prostate cancer (CRPC). Current research has demonstrated that the development of novel AR-V7 degraders holds broad prospects and is expected to serve as a clinical therapeutic regimen for this disease. In the present work, we utilized structural analogs of enzalutamide to conjugate a silicon-containing hydrophobic tag (SiHyT) moiety via Click chemistry, achieving the selective degradation of the androgen receptor (AR) and AR-V7. Mechanistic studies revealed that the degrader disrupted the interactions between AR/AR-V7 and HSP90. This disruption further prompted the E3 ubiquitin ligase helicase-like transcription factor (HLTF) to recognize AR and AR-V7, followed by their ubiquitination and degradation in CRPC cell lines. Additionally, the active compound exhibited favorable pharmacokinetic properties and metabolic profiles. In both <em>in vitro</em> and <em>in vivo</em> experiments, this degrader displayed more potent activity than enzalutamide in inhibiting the proliferation and migration of CRPC cells. This study expands the application scope of the silicon-containing hydrophobic tag (SiHyT) strategy and provides an alternative design concept for the development of drugs targeting the degradation of AR/AR-V7 in the treatment of CRPC.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118617"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew M. Thompson , Nils-Jørgen K. Dal , Francesca Boldrin , Noelia Alonso-Rodriguez , Gabriela Schäfer , Kerstin Johann , Martin Speth , Laura Cioetto-Mazzabò , Adrián Pál , Jana Korduláková , Matthias Barz , Federico Fenaroli , William A. Denny , Gareth Griffiths
{"title":"New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation","authors":"Andrew M. Thompson , Nils-Jørgen K. Dal , Francesca Boldrin , Noelia Alonso-Rodriguez , Gabriela Schäfer , Kerstin Johann , Martin Speth , Laura Cioetto-Mazzabò , Adrián Pál , Jana Korduláková , Matthias Barz , Federico Fenaroli , William A. Denny , Gareth Griffiths","doi":"10.1016/j.ejmech.2026.118622","DOIUrl":"10.1016/j.ejmech.2026.118622","url":null,"abstract":"<div><div>Third-generation derivatives of the tuberculosis drug pretomanid featuring acetylene-bridged aryl-heteroaryl or heterotriaryl side chains were designed as novel agents for nanoparticle-based delivery, seeking better efficacy and safety. While all nitro compounds retained excellent activity against <em>Mycobacterium tuberculosis</em>, several examples in the latter class excelled as having potency superior to the original lead (<strong>7</strong>) but equivalent to or reduced lipophilicity, implying enhanced lipophilic efficiency. Initial studies suggested a similar mode of action against the related fish pathogen, <em>M. marinum</em>; therefore, fourteen candidates were further assessed as micellar formulations in <em>M. marinum-</em>infected zebrafish embryo assays. Overall, the best new analogue was <strong>14</strong> (the 6-amino-linked congener of <strong>7</strong>), which was non-toxic and displayed efficacy comparable to <strong>7</strong> in both the blood and neural tube <em>M. marinum</em> infection models. Lead <strong>14</strong> also exhibited high microsomal stability, moderate cell permeability in an MDR1-MDCKII screen, and an enhanced pharmacokinetic profile in mice, with 93 % oral bioavailability.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118622"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}